ERBB2 and gastric cancer: Since the combination of chemo-immunotherapy became the new first-line standard of care in PDL1-positive, HER2-negative advanced GC [7], a marked interest was shown in the possibility of identifying and monitoring the PDL1 status in a non-invasive way.